Business
Hikma launches Triazolam Tablets
Hikma launches Triazolam Tablets.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n \nRNS Number : 6733H Hikma Pharmaceuticals Plc 19 November 2018 \n\nLondon, 19 November 2018 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) announces that Hikma Pharmaceuticals USA Inc., formerly known as West-Ward Pharmaceuticals Corp., has launched Triazolam Tablets, 0.125mg and 0.25mg the generic equivalent to Halcion®.1\nHikma's Triazolam tablets are indicated for the short-term treatment of insomnia (generally seven to ten days). Use for more than two or three weeks requires complete reevaluation of the patient. \nPrescriptions for triazolam tablets should be written for short-term use (seven to ten days) and it should not be prescribed in quantities exceeding a one-month supply.\nAccording to IQVIA, US sales of Triazolam Tablets were approximately $27 million in the 12 months ending September 2018.\nBrian Hoffmann, President, Generics Division, said, \"We are excited to launch Triazolam Tablets, improving patients' access to this product. This launch highlights the successful execution of our strategy to develop more differentiated products by leveraging our specialised manufacturing capabilities.\"\n1 Halcion® is a registered trademark of Pfizer\n-- ENDS -\n \nEnquiries\nHikma Pharmaceuticals PLC\n\n\n\nSusan Ringdal\nEVP, Strategic Planning and Global Affairs\n\n\n+44 (0)20 7399 2760/ +44 7776 477050\[email protected]\n \n\n\n\nFTI Consulting \n\n\n\nBen Atwell/Brett Pollard\n\n\n+44 (0)20 3727 1000\n\n\n\n \nAbout Hikma\nHikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our com...